# SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

> **NCT03004183** · PHASE2 · COMPLETED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 57 (actual)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer
- Metastatic Triple-negative Breast Cancer

## Interventions

- **BIOLOGICAL:** ADV/HSV-tk
- **DRUG:** Valacyclovir
- **RADIATION:** SBRT
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03004183
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2022-07-22
- **Final completion:** 2024-01-09
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004183, "SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03004183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*